Researchers ID molecule linked to aggressive cancer growth, spread

Nov 13, 2008

Researchers at the University of Michigan Comprehensive Cancer Center have found a genetic marker that controls an enzyme present in aggressive and metastatic cancer. The study suggests an absence of microRNA-101 is related to high expression of the protein EZH2, which was previously shown to be active in metastatic cancers. MicroRNA's are molecules that help regulate gene expression. miR-101 is one of few miRNA's shown to play such an important role in the development of cancer.

In this study, the researchers found miR-101 is significantly underexpressed in a variety of cancers, including prostate and breast cancer. Essentially, the researchers believe that miR-101 suppresses the EZH2 protein. When miR-101 is lost in cancer, EZH2 expression is uncontrolled, and that haywire in-gene expression leads to more aggressive cancer growth.

The findings suggest that loss of miR-101 could potentially be used as a marker of aggressive or metastatic cancer. Replacement of miR-101 in cancers could also be developed as a future cancer treatment.

The study will be published online in the journal Science on Nov. 13. It was led by Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and investigator of the Howard Hughes Medical Institute.

Source: University of Michigan

Explore further: Opdivo approval expanded to include lung cancer

add to favorites email to friend print save as pdf

Related Stories

Why your laptop battery won't kill you

2 hours ago

News on Tuesday that major U.S. airlines are no longer going to ship powerful lithium-ion batteries might lead some to fret about the safety of their personal electronic devices.

Visa, MasterCard moving into mobile pay in Africa

2 hours ago

Americans may just be getting used to mobile pay, but consumers in many African countries have been paying with their phones for years. Now payment processors Visa and MasterCard want to get a slice of that market, and are ...

Lightning plus volcanic ash make glass

2 hours ago

In their open-access paper for Geology, Kimberly Genareau and colleagues propose, for the first time, a mechanism for the generation of glass spherules in geologic deposits through the occurrence of volcan ...

Recommended for you

Opdivo approval expanded to include lung cancer

8 hours ago

(HealthDay)—U.S. Food and Drug Administration approval of Opdivo (nivolumab) has been expanded to include advanced non-small cell lung cancer (NSCLC), the agency said Wednesday in a news release.

First-of-its kind reference on pelvic malignancies

10 hours ago

Loyola University Medical Center radiation oncologist William Small, Jr., MD, FACRO, FACR, FASTRO, is co-editor of Pelvic Malignancy and its Consequences, the first-of-its kind stand-alone reference on the subject.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.